Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer

Dachineni,Rakesh; Kumar,D. Ramesh; Callegari,Eduardo; Kesharwani,Siddharth S.; Sankaranarayanan,Ranjini; Seefeldt,Teresa; Tummala,Hemachand; Bhat,G. Jayarama

doi:10.3892/ijo.2017.4167

Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer

Authors:
- Rakesh Dachineni
- D. Ramesh Kumar
- Eduardo Callegari
- Siddharth S. Kesharwani
- Ranjini Sankaranarayanan
- Teresa Seefeldt
- Hemachand Tummala
- G. Jayarama Bhat
View Affiliations

Affiliations: Department of Pharmaceutical Sciences and Translational Cancer Research Center, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD 57007, USA, SD-BRIN Proteomic Facility, University of South Dakota School of Medicine, Vermillion, SD 57069, USA
Published online on: October 19, 2017 https://doi.org/10.3892/ijo.2017.4167
Pages: 1661-1673
Copyright: © Dachineni et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aspirin's potential as a drug continues to be evaluated for the prevention of colorectal cancer (CRC). Although multiple targets for aspirin and its metabolite, salicylic acid, have been identified, no unifying mechanism has been proposed to clearly explain its chemopreventive effects. Our goal here was to investigate the ability of salicylic acid metabolites, known to be generated through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent kinase (CDK) inhibitors to gain new insights into aspirin's chemopreventive actions. Using in vitro kinase assays, for the first time, we demonstrate that salicylic acid metabolites, 2,3-dihydroxybenzoic acid (2,3-DHBA) and 2,5-dihydroxybenzoic acid (2,5-DHBA), as well as derivatives 2,4-dihydroxybenzoic acid (2,4-DHBA), 2,6-dihydroxybenzoic acid (2,6-DHBA), inhibited CDK1 enzyme activity. 2,3-DHBA and 2,6-DHBA did not inhibit CDK2 and 4; however, both inhibited CDK-6 activity. Interestingly, another derivative, 2,4,6-trihydroxybenzoic acid (2,4,6-THBA) was highly effective in inhibiting CDK1, 2, 4 and 6 activity. Molecular docking studies showed that these compounds potentially interact with CDK1. Immunoblotting experiments showed that aspirin acetylated CDK1, and pre-incubation with salicylic acid and its derivatives prevented aspirin-mediated CDK1 acetylation, which supported the data obtained from molecular docking studies. We suggest that intracellularly generated salicylic acid metabolites through CYP450 enzymes within the colonic epithelial cells, or the salicylic acid metabolites generated by gut microflora may significantly contribute to the preferential chemopreventive effect of aspirin against CRC through inhibition of CDKs. This novel hypothesis and mechanism of action in aspirin's chemopreventive effects opens a new area for future research. In addition, structural modification to salicylic acid derivatives may prove useful in the development of novel CDK inhibitors in cancer prevention and treatment.

View Figures

View References

1	Patrignani P and Patrono C: Aspirin and Cancer. J Am Coll Cardiol. 68:967–976. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hul MA, Logan RF, Rothwell PM, Schrör K and Baron JA: Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res (Phila). 5:164–178. 2012. View Article : Google Scholar
3	Sostres C, Gargallo CJ and Lanas A: Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther. 5:40–49. 2014. View Article : Google Scholar : PubMed/NCBI
4	Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bosetti C, Rosato V, Gallus S, Cuzick J and La Vecchia C: Aspirin and cancer risk: A quantitative review to 2011. Ann Oncol. 23:1403–1415. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP and Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar
7	Alfonso L, Ai G, Spitale RC and Bhat GJ: Molecular targets of aspirin and cancer prevention. Br J Cancer. 111:61–67. 2014. View Article : Google Scholar : PubMed/NCBI
8	Pedersen AK and FitzGerald GA: Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 311:1206–1211. 1984. View Article : Google Scholar : PubMed/NCBI
9	Bahar FG and Imai T: Aspirin hydrolysis in human and experimental animal plasma and the effect of metal cations on hydrolase activities. Drug Metab Dispos. 41:1450–1456. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hutt AJ, Caldwell J and Smith RL: The metabolism of aspirin in man: A population study. Xenobiotica. 16:239–249. 1986. View Article : Google Scholar : PubMed/NCBI
11	Bojić M, Sedgeman CA, Nagy LD and Guengerich FP: Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 73:49–56. 2015. View Article : Google Scholar
12	Grootveld M and Halliwell B: 2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Biochem Pharmacol. 37:271–280. 1988. View Article : Google Scholar : PubMed/NCBI
13	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
14	Peyressatre M, Prével C, Pellerano M and Morris MC: Targeting cyclin-dependent kinases in human cancers: From small molecules to Peptide inhibitors. Cancers (Basel). 7:179–237. 2015. View Article : Google Scholar
15	Brown NR, Korolchuk S, Martin MP, Stanley WA, Moukhametzianov R, Noble ME and Endicott JA: CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun. 6:67692015. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hamilton E and Infante JR: Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
18	Roskoski R Jr: Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 107:249–275. 2016. View Article : Google Scholar : PubMed/NCBI
19	Dachineni R, Ai G, Kumar DR, Sadhu SS, Tummala H and Bhat GJ: Cyclin A2 and CDK2 as novel targets of aspirin and salicylic acid: A potential role in cancer prevention. Mol Cancer Res. 14:241–252. 2016. View Article : Google Scholar :
20	Ai G, Dachineni R, Kumar DR, Marimuthu S, Alfonso LF and Bhat GJ: Aspirin acetylates wild type and mutant p53 in colon cancer cells: Identification of aspirin acetylated sites on recombinant p53. Tumour Biol. 37:6007–6016. 2016. View Article : Google Scholar
21	Ai G, Dachineni R, Muley P, Tummala H and Bhat GJ: Aspirin and salicylic acid decrease c-Myc expression in cancer cells: A potential role in chemoprevention. Tumour Biol. 37:1727–1738. 2016. View Article : Google Scholar
22	Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA and Bhat GJ: Aspirin inhibits camptothecin-induced p21C IP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol. 34:597–608. 2009.PubMed/NCBI
23	Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE and Berendsen HJ: GROMACS: Fast, flexible, and free. J Comput Chem. 26:1701–1718. 2005. View Article : Google Scholar : PubMed/NCBI
24	Senderowicz AM: Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 17:313–320. 1999. View Article : Google Scholar
25	Sausville EA: Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 8(Suppl): S32–S37. 2002. View Article : Google Scholar : PubMed/NCBI
26	Welburn JP, Tucker JA, Johnson T, Lindert L, Morgan M, Willis A, Noble ME and Endicott JA: How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J Biol Chem. 282:3173–3181. 2007. View Article : Google Scholar
27	Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120. 1998. View Article : Google Scholar : PubMed/NCBI
28	Thun MJ, Jacobs EJ and Patrono C: The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 9:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dovizio M, Tacconelli S, Sostres C, Ricciotti E and Patrignani P: Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel). 5:1346–1371. 2012. View Article : Google Scholar
30	Lichtenberger LM, Fang D, Bick RJ, Poindexter BJ, Phan T, Bergeron AL, Pradhan S, Dial EJ and Vijayan KV: Unlocking aspirin's chemopreventive activity: Role of irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prev Res (Phila). 10:142–152. 2017. View Article : Google Scholar
31	Patrignani P, Sacco A, Sostres C, Bruno A, Dovizio M, Piazuelo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, et al: Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: Implications for the chemoprevention of colorectal cancer. Clin Pharmacol Ther. 102:52–61. 2017. View Article : Google Scholar
32	Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 265:956–959. 1994. View Article : Google Scholar : PubMed/NCBI
33	Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, et al: The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 336:918–922. 2012. View Article : Google Scholar : PubMed/NCBI
34	Klessig DF, Tian M and Choi HW: Multiple targets of salicylic acid and its derivatives in plants and animals. Front Immunol. 7:2062016. View Article : Google Scholar : PubMed/NCBI
35	Manach C, Scalbert A, Morand C, Rémésy C and Jiménez L: Polyphenols: Food sources and bioavailability. Am J Clin Nutr. 79:727–747. 2004.PubMed/NCBI
36	Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S and Prasad PD: Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10:193–199. 2008. View Article : Google Scholar : PubMed/NCBI
37	Gervot L, Carrière V, Costet P, Cugnenc PH, Berger A, Beaune PH and de Waziers I: CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ Toxicol Pharmacol. 2:381–388. 1996. View Article : Google Scholar : PubMed/NCBI
38	Thelen K and Dressman JB: Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 61:541–558. 2009. View Article : Google Scholar : PubMed/NCBI
39	Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE and Zeldin DC: The human intestinal cytochrome P450 'pie'. Drug Metab Dispos. 34:880–886. 2006. View Article : Google Scholar : PubMed/NCBI
40	Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S and Murray GI: Cytochrome P450 profile of colorectal cancer: Identification of markers of prognosis. Clin Cancer Res. 11:3758–3765. 2005. View Article : Google Scholar : PubMed/NCBI
41	Paterson JR, Blacklock C, Campbell G, Wiles D and Lawrence JR: The identification of salicylates as normal constituents of serum: A link between diet and health? J Clin Pathol. 51:502–505. 1998. View Article : Google Scholar : PubMed/NCBI
42	Juurlink BH, Azouz HJ, Aldalati AM, AlTinawi BM and Ganguly P: Hydroxybenzoic acid isomers and the cardiovascular system. Nutr J. 13:632014. View Article : Google Scholar : PubMed/NCBI
43	Arunachalam M, Mohan N, Sugadev R, Chellappan P and Mahadevan A: Degradation of (+)-catechin by Acinetobacter calcoaceticus MTC 127. Biochim Biophys Acta. 1621:261–265. 2003. View Article : Google Scholar : PubMed/NCBI
44	Gao K, Xu A, Krul C, Venema K, Liu Y, Niu Y, Lu J, Bensoussan L, Seeram NP, Heber D, et al: Of the major phenolic acids formed during human microbial fermentation of tea, citrus, and soy flavonoid supplements, only 3,4-dihydroxyphenylacetic acid has antiproliferative activity. J Nutr. 136:52–57. 2006.
45	Seeram NP, Bourquin LD and Nair MG: Degradation products of cyanidin glycosides from tart cherries and their bioactivities. J Agric Food Chem. 49:4924–4929. 2001. View Article : Google Scholar : PubMed/NCBI
46	Paterson JR and Lawrence JR: Salicylic acid: A link between aspirin, diet and the prevention of colorectal cancer. QJM. 94:445–448. 2001. View Article : Google Scholar : PubMed/NCBI
47	Kamiloglu S, Capanoglu E, Grootaert C and Van Camp J: Anthocyanin absorption and metabolism by human intestinal Caco-2 cells - A review. Int J Mol Sci. 16:21555–21574. 2015. View Article : Google Scholar : PubMed/NCBI
48	Kresty LA, Mallery SR and Stoner GD: Black raspberries in cancer clinical trials: Past, present and future. J Berry Res. 6:251–261. 2016. View Article : Google Scholar : PubMed/NCBI
49	Dovizio M, Bruno A, Tacconelli S and Patrignani P: Mode of action of aspirin as a chemopreventive agent. Prospects for Chemoprevention of Colorectal Neoplasia. Springer; pp. 39–65. 2013, View Article : Google Scholar